Potential Neurogenesis and Neuroprotective Effects of Epigallocatechin-3-gallate (EGCG) in Green Tea (Camellia sinensis) Through Microglia M2 Induction Process and NLRP3 Inhibition as an Innovation for Ischemic Stroke Adjuvant Therapy: A Review Innas Safira Putri 1 , Tazkia Nafs Robbani 1 , Dinda Divamillenia 1 , Octaviana Galuh Pratiwi 1 , Reny I’tishom 2,* Email: ritishom@fk.unair.ac.id 1 Medical Program, Faculty of Medicine Universitas Airlangga, 60132, Surabaya, East Java, Indonesia 2 Department of Biomedical Science, Faculty of Medicine Universitas Airlangga, 60132, Surabaya, East Java, Indonesia Abstract Stroke is a condition that occurs when blood vessels in the brain become obstructed or rupture, cutting off blood flow to the brain and causing brain cells to die. Stroke is divided into two types based on the cause: ischemic stroke and hemorrhagic stroke. Ischemic stroke is the most common kind of stroke, which accounts for approximately 87% of all strokes. The high prevalence of ischemic stroke has far-reaching consequences for society. Because ischemic stroke is still common and treatment options are limited, a therapeutic breakthrough that can help reduce stroke mortality and morbidity, particularly ischemic stroke, is required. One of the advancements that can be made is the consumption of green tea (Camellia sinensis), which has neurogenetic and neuroprotective benefits. This literature was compiled through online searches engines using Pubmed, Sciencedirect, NIH NCBI, and Google Scholar instruments. In this way, green tea with the active ingredient Epigallocatechin-3-gallate (EGCG) has the potential to induce neurogenesis in ischemic conditions by causing microglia to polarize to M2 and can inhibit pro-inflammatory mediators by inhibiting NOD-like Receptor Protein-3 (NLRP3), thereby inhibiting the pyroptosis process. As a result, EGCG has the potential to become a neuroprotective ingredient. These two major processes will aid in the recovery of ischemic stroke patients. Keywords: EGCG, Green Tea, Camellia sinensis, M2 Microglia, NLRP3, Ischemic Stroke, Neurogenesis, Neuroprotective 1. Introduction Stroke is a disease of the blood vessels in the brain, specifically the condition of blood vessel blockage or rupture, which cuts off blood flow to the brain and causes cell death in some areas of the brain [1]. Because cell death in the brain results in the loss of neurological function, stroke is one of the leading causes of death and disability worldwide. It is worth noting that stroke is the world's second leading cause of death and third leading cause of disability [2]. Stroke is classified into two types based on its etiology: ischemic stroke and hemorrhagic stroke. Ischemic stroke got the first rank as the most common type of stroke (87%) [3] caused by cerebral artery occlusion [1]. The high prevalence of ischemic stroke has an impact on the community, one of which is a high economic burden, both in terms of treatment and due to the patient's disability. Until now, the Food and Drug Administration has approved only the rtPA (Alteplase) class of thrombolytic therapy for use in stroke patients, but the safety and efficacy of this therapy are still limited [4]. Because of the high prevalence and limited treatment options, it is critical to develop a therapeutic innovation that will improve the well-being 45 www.ijrp.org IJRP 2022, 92(1), 45-52; doi:.10.47119/IJRP100921120222656